OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2026

OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2026

  • September 2017 •
  • 227 pages •
  • Report ID: 4392662 •
  • Format: PDF
OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2026

Summary
Osteoarthritis (OA) is the most common joint disease, affecting over 27 Millionpeople in the US alone in 2005. It is a major cause of disability and pain among the elderly in the western world, second only to cardiovascular (CV) disease. An estimated 10-15% of adults over 60 years of age have some degree of OA and with an aging population; the total number of OA cases is likely to grow.

Osteoarthritis (OA) market is expected to increase at a compound annual growth rate (CAGR) of 8.1%. The US contributed 68% of the market share in 2016, which is linked to the large OA population and high drug prices in this market. Multiple biologic drug launches are expected during the forecast period and will lead to rapid market growth in the US and Japan, posting CAGRs of 9.2% and 6.1%, respectively. The 5EU will have the slowest market growth (at a CAGR of 4.8%), as only two drugs are expected to launch in this region during the forecast period. Although both therapies are biologics, they will likely have a slow uptake due to the associated high price.

The main drivers of growth in the OA market include the increasing numbers of OA cases and the expected launches of multiple biologic drugs, which are forecast to radically change the OA market and add over $1.7Billion in sales to the market in 2026.

Current OA therapy landscape offers a large opportunity for pharmaceutical companies to develop drugs with new MOAs and disease-modifying effects as the pathophysiology of OA is elucidated and new targets identified. This opportunity could be exploited by supporting academic institutions in their ongoing efforts to identify new disease targets and biomarkers. Companies may also consider in-licensing pipeline products with novel analgesic mechanisms or disease-modifying potential.

The report "OpportunityAnalyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2026", provides overview of OA, including epidemiology (separation between symptomatic and radiographic patients), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following -
- Topline OA market revenue from 2016-2026. ACOT and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting OA therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global OA therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report:Ampio Pharmaceuticals, Cara Therapeutics, Cellular Biomedicine Group, Centrexion Therapeutics, Eli Lilly, Flexion Therapeutics, Healthcare Life Sciences, Kolon Life Sciences, Mitsubishi Tanabe Pharma, Mundipharma, Ono Pharmaceutical.

Scope
- Overview of OA, including epidemiology (separation between symptomatic and radiographic patients), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline OA market revenue from 2016-2026. ACOT and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting OA therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global OA therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global OA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the OA therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.